Independent
Tenure on this board
23.4 yrs
Also a director at
Kyverna Therapeutics Inc (KYTX)Intellia Therapeutics Inc (NTLA)
5 nominees · 5 ballot items.
Elect five directors; ratify Deloitte & Touche LLP as independent auditor for 2026; advisory (non-binding) approval of named executive officer compensation; advisory (non-binding) vote on the frequency of future say-on-pay votes (Board recommends annual); approve an amendment to the 2024 Equity Incentive Plan to increase the share reserve; and transact any other properly brought business.
Vote to elect five directors (Fred E. Cohen, R. Bryan Riggsbee, Suresh Gunasekaran, Michael D. Goldberg and John W. Hanna) to serve until the 2027 annual meeting or until their successors are elected and qualified.
Ratify the appointment of Deloitte & Touche LLP as CareDx's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Non-binding, advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.
Non-binding, advisory vote to select the preferred frequency (ONE YEAR, TWO YEARS, or THREE YEARS) for future advisory votes on executive compensation; the Board recommends ONE YEAR (annual votes).
Approve an amendment to the 2024 Equity Incentive Plan to increase the number of shares available for issuance by 1,600,000 shares (and a corresponding increase in ISOs), subject to adjustment under the plan.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAMCO INC /NY/ | 6.5% | 3,336,409 | $58M |
| 2 | STATE STREET CORP | 5.3% | 2,760,385 | $48M |
| 3 | BlackRock, Inc. | 4.6% | 2,359,783 | $41M |
| 4 | ARK Investment Management LLC | 4.3% | 2,227,556 | $39M |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4.2% | 2,191,000 | $38M |
| 6 | BRAIDWELL LP | 4.2% | 2,173,146 | $38M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 2,160,457 | $38M |
| 8 | Boston Partners | 3.6% | 1,883,534 | $33M |
| 9 | GAGNON SECURITIES LLC | 3.4% | 1,761,874 | $31M |
| 10 | BlackRock, Inc. | 3.0% | 1,543,216 | $27M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.